Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Company Overview

Chugai Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines.

Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.

Key Stats

• Today's Range: $21.41 to $21.76
• 50-Day Range: $20.90 to $23.77
• 52-Week Range: $20.27 to $34.84
• Volume: 133,526 shs
• Average Volume: 226,508 shs
• Market Capitalization: $70.93 billion
• P/E Ratio: 23.42
• Dividend Yield: 2.88%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Chugai Pharmaceutical Stock Analysis - MarketRank™

Chugai Pharmaceutical scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Chugai Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Chugai Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 28.13%

Earnings Growth

Earnings for Chugai Pharmaceutical are expected to grow by 28.13% in the coming year, from $0.96 to $1.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chugai Pharmaceutical is 23.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chugai Pharmaceutical is 23.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.81.

Price to Book Value per Share Ratio

Chugai Pharmaceutical has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Chugai Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chugai Pharmaceutical has recently decreased by 54.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Chugai Pharmaceutical pays a meaningful dividend of 2.75%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chugai Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Chugai Pharmaceutical is 67.39%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 50.41% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.50

News Sentiment

Chugai Pharmaceutical has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Chugai Pharmaceutical this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for CHGCY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.01% of the stock of Chugai Pharmaceutical is held by institutions.

Company Calendar

• Last Earnings: 7/24/2026
• Today: 8/15/2026
• Next Earnings (Estimated): 10/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CHGCY
• CIK: 1453934
• Web: www.chugai-pharm.co.jp
• Phone: (133) 281-6611
• Fax: N/A
• Employees: 7,778
• Year Founded: 1925

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 23.42
• Forward P/E Ratio: 22.45
• P/E Growth: N/A
• Net Income: $2.91 billion
• Net Margins: 35.09%
• Pretax Margin: 47.52%
• Return on Equity: 23.71%
• Return on Assets: 19.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $8.41 billion
• Price / Sales: 8.43
• Cash Flow: $0.91 per share
• Price / Cash Flow: 23.64
• Book Value: $4.12 per share
• Price / Book: 5.23

Miscellaneous

• Outstanding Shares: 3,291,427,000
• Free Float: N/A
• Market Cap: $70.93 billion
• Optionable: Not Optionable
• Beta: 0.60